Georgiamune raises $93M Series B to advance cancer, autoimmune treatments
What's the deal? Gaithersburg-based Georgiamune, a clinical-stage biotech developing treatments for cancer and autoimmune diseases, raised $92.69 million in a Series B round. Prevail Private Capital and Mubadala Capital led the financing, which set the company's pre-money valuation at $296.31 million.
Why now? The round lands amid a flurry of local funding activity: four Montgomery County companies raised a combined $117.66 million in August across food manufacturing, life sciences, and insurance technology.
What's the endgame? Georgiamune, which employs almost 30 people, focuses on treatments for cancer and autoimmune diseases. The Series B — structured as B1 and B2 tranches — gives it fresh capital to push those programs forward.
The context: Georgiamune's raise stands out among US Series B rounds in health, ranking in roughly the 92nd percentile by size across a sample of 3,711 comparable deals. That puts it well above the typical health-sector Series B.
The signal: The August tally shows venture money flowing into a cluster of smaller, specialised firms outside the usual coastal hubs — from Rockville frozen-food maker Jesse & Ben's, which raised $15 million in Series A funding, to Bethesda insurtech EnsuriseDealroom has a profile for this one. Try Dealroom → at $9.22 million and Gaithersburg rare-disease developer Cerium Pharmaceuticals at $750,001. Georgiamune's outsized round anchors that momentum in Maryland's life sciences corridor.
Read more: thinkmoco.com
Image credit: Georgiamune
